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A Paarl neurosurgeon claims to be on his 
way to a world first in repairing spinal 
cord injuries using therapeutic stem cell 
cloning, having removed 35 mm from the 
spinal cord of a quadriplegic man and 
injecting a ‘special’ matrix of the cells into 
the defect. 
Dr Adriaan Liebenberg asserts that the 
stem cell work via his surgery is responsible 
for enhanced arm strength and the return 
of (delayed) sensation to the hands and feet 
of 32-year-old Tommie Prins, of Milnerton, 
paralysed in a sand-bar diving accident six 
years ago. However, two of the country’s 
top stem cell experts, regulatory authorities 
and university ethicists expressed deep alarm. 
Their concerns are that neither Liebenberg 
nor his partner, Dr Gert Jordaan (who has 
a PhD in Agriculture), have obtained ethical 
approval, subjected their work to peer review, 
published any of it, or secured Medicines 
Control Council (MCC) go-ahead. Jordaan 
earned a suspended jail sentence two years 
ago for doing spine-severing work on 
monkeys without the correct permit, though 
he did obtain Health Ministry approval for 
his research via the then incumbent, Barbara 
Hogan, thus bypassing other regulatory 
structures. The Health Professions Council of 
South Africa (HPCSA)’s Human Rights and 
Ethics Committee later over-rode Hogan’s 
decision, citing Jordaan’s connection with a 
medical doctor (Liebenberg), to justify its 
intervention. Dr Joey Gouws, Director of the 
MCC’s Inspectorate and Law Enforcement, 
told Izindaba that no clinical trial using stem 
cell therapy has been approved by her body. 
An HPCSA spokesperson added that any 
unproven or ‘secret’ remedy was unacceptable 
for use in the treatment of a patient. 
Liebenberg showed newspaper journalists 
a 2008 HPCSA letter addressed to Jordaan 
and one of Liebenberg’s patients (one Mr 
Burger), purporting to give conditional 
approval for their work, plus the approval 
letter from Hogan. However, the HPCSA said 
it had followed up its own letter the following 
year, laying down specific conditions and 
asking several probing questions – to which 
it never received answers. Professor Ames 
Dhai, head of Bio-ethics at the University 
of the Witwatersrand, and member of the 
eponymous HPCSA committee at the time, 
confirmed vetting Liebenberg’s application 
and over-riding Hogan’s approval. ‘Our view 
was we could not support something like 
that,’ she said, adding that ‘without robust 
research and full-phase clinical trials it was 
extremely difficult to say whether outcomes 
were harmful or beneficial’.
Absence of systematic, scientific 
scrutiny – Dhai
‘You cannot use un-researched interventions 
in the name of therapy. You can’t hide behind 
therapy. It must stand up to systematic, 
scientific scrutiny and we don’t have that yet.’ 
She believes if it can be shown that Jordaan 
and Liebenberg are using therapy without 
complying with legislation or approval from 
government structures, they are acting 
illegally. Professor Michael Pepper, Director 
of the Institute for Cellular and Molecular 
Medicine at the University of Pretoria and 
Professor Susan Kidson, Deputy Dean of 
Medicine at the University of Cape Town 
(and a widely acknowledged cell and 
developmental biologist), agreed that there 
had so far been no approval in South Africa 
(SA) for such stem cell research. Added 
Pepper: ‘I can almost guarantee that this 
is not an accepted form of therapy’. To 
his knowledge the procedure had never 
been done in SA before. He conceded 
that were its success proven, it would be a 
‘major breakthrough’ globally, but stressed 
that nobody anywhere in the world had 
‘even got close to repair yet’. He said it was 
‘entirely possible’ that the spinal cord injury 
(between C4/C5) was partial and had begun 
recovering spontaneously, with the stem cell 
addition purely co-incidental.
Tommie Prins lost all feeling from about 
two fingers above his nipples to his toes in 
the accident. Nearly three years later, after 
some dedicated physiotherapy, he began to 
regain movement in his right arm. Pepper 
says this strongly suggests that the spinal 
cord laceration was incomplete. Liebenberg 
performed two surgical procedures, the 
first on 10 October last year in which he 
removed 35 mm of Prins’ spine between C3 
and C5, injecting cells derived by somatic 
cell nuclear transfer (SCNT), also known as 
therapeutic cloning, into the defect. SCNT 
uses a donor egg and skin fibroblasts from the 
patient which are considered to be autologous 
embryonic stem cells. The second surgical 
procedure, on 24 October, was to augment 
the mix and fix a residual fluid leak from 
the spinal cord. Describing the first six-
hour procedure, Liebenberg said scar tissue 
‘Pioneer’ Paarl neuro sets 
alarm bells ringing
Dr Adriaan Liebenberg.        Photos courtesy of Die Burger.
Their concerns are that neither 
Liebenberg nor his partner, Dr 
Gert Jordaan (who has a PhD 
in Agriculture), have obtained 
ethical approval, subjected their 
work to peer review, published 
any of it, or secured Medicines 
Control Council (MCC) go-ahead.
Izindaba
9  January 2013, Vol. 103, No. 1  SAMJ
that separated the two ends of the spinal 
cord was removed while electrophysiological 
monitoring by a neurophysiologist was done 
to limit damage to the functioning sections of 
the spinal cord. After the scar was completely 
removed, a special matrix containing 
autologous embryonic stem cells and growth 
factors were sealed in the defect. He said 
both procedures were carried out without 
any complications and the patient initially 
had no decrease in function. Since then there 
had been improvement in the function of 
both arms, in existing muscle function and 
strength, and new muscle movement in three 
muscle groups on the right and two muscle 
groups on the left. ‘The patient has return 
of partial sensation throughout the body. 
This represents a staggering early response. 
The interim and final clinical results will be 
reported on by an independent clinician’, 
Liebenberg added.
Big gaps in legislation a major issue 
– Pepper
Pepper said the controversy highlighted 
the dangers related to both the procedure 
itself and the unpredictable behaviour of 
the stem cells used at the site of the injury, 
warning that developmentally immature 
cells (embryonic or pluripotent) could 
go on to form tumours. The procedure 
risked infection, pain and further loss of 
sensation/function. If the patient’s lesion 
was incomplete, ‘one has to question the 
justification for complete removal of 35 
mm of the spinal cord’. Another issue it 
raised was the fragmentary, conflicting 
and in some cases ‘frankly incorrect’ 
definitions governing such procedures in 
the existing legislation. This ‘legislative 
vacuum’ created opportunities for the 
development of unethical and unregulated 
practices in the SA stem cell field. While 
former Health Minister Barbara Hogan 
had authorised the initial research in 
October 2008, this in no way exempted the 
researchers from obtaining clearance from 
an ethics committee or from registering 
the procedure with the MCC, or obtaining 
peer review. 
Pepper said he was not out to halt the 
progress of science or deny patients any 
potential benefits, but rather to protect 
patients against foreseeable problems and 
to protect the doctors involved against 
complications ‘unforeseen under normal/
reasonable circumstances in a society 
which is becoming increasingly litigious’. 
(Prins signed indemnity for the procedure 
and has undertaken to give Liebenberg 
exclusive media rights should the therapy 
work.) Professor Kidson said that to date 
there had been no successful stem cell 
derivations from embryos obtained by 
SCNT (therapeutic cloning) and ‘most 
certainly no such cloned cells have been 
used for any therapeutic purpose’. Cell 
derivation not carefully quality-assured 
would create too great a risk of rogue 
cells (teratogenic, aberrant differentiation, 
for example into bone or muscle cells), 
she warned. The only stem cell line 
purportedly derived by human nuclear 
transfer had subsequently been shown 
to originate by parthenogenesis rather 
than by reprogramming from the somatic 
nucleus. She said that as far as she had 
been able to ascertain, nobody had ever 
tried to introduce such cells into humans 
before.
Mrs Marzelle Haskins, chief of 
PharmaEthics (one of only two bodies that 
can approve private clinical trials), said that 
while she had previously approved ‘normal’ 
neurological clinical trials of Liebenberg’s 
(‘Parkinson’s and things like that’), she had 
never approved stem cell research. She 
declared herself ‘very nervous’ of stem cell 
research and recalled an e-mail several years 
ago querying whether it was an approved 
therapeutic method, which she had 
forwarded to Professor Dhai. ‘It might have 
been Liebenberg I cannot say for certain 
now,’ she added.
Lab ‘a tourist attraction waiting to 
happen’ – Liebenberg
Asked for an interview, Liebenberg said he 
was ‘not at the point of publishing anything 
in a medical journal’ and referred Izindaba 
to the Melomed Hospital group for ‘the 
news elements’. He told an Afrikaans daily 
morning newspaper which confronted him 
with the experts’ objections and their risk 
warnings: ‘We’re still going to do five to ten 
patients before we broadcast it in a scientific 
forum. Just now you get some clot in India 
copying us.’ He refused to disclose where the 
stem cell laboratory was, adding that ‘in four 
months or so we’ll surely be taking tour groups 
through it’. An e-mailed indemnity form 
sent to Tommie Prins reads: ‘I understand 
that the procedure I are (sic) consenting to 
is an experimental procedure and that there 
is no clinical data to predict whether this 
procedure will be harmful or beneficial. I 
document that I will have no claim arising 
from this procedure or any complications 
thereof against Dr Liebenberg, members of 
his team, or Melomed Hospital Holdings.’ A 
detailed informed-consent paragraph follows. 
Melomed Hospital Holdings said they accepted 
the documentation provided to them by Dr 
Liebenberg ‘in good faith, deliberated the 
ethical considerations therein and on that basis 
allowed him to perform this ground-breaking 
stem cell transplant operation at our Melomed 
Bellville Private Hospital’. The hospital group 
said it also received various permissions from 
a ‘wide range of authorities’ – all of which had 
said there was no reason why the doctor could 
not proceed.
Both Kidson and Pepper warned that 
the experimental procedure could do SA’s 
international scientific reputation great harm. 
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Tommie Prins credits Liebenberg for the return of 
sensation and movement to his limbs.
He told an Afrikaans daily 
morning newspaper which 
confronted him with the experts’ 
objections and their risk 
warnings: ‘We’re still going to 
do five to ten patients before we 
broadcast it in a scientific forum. 
Just now you get some clot in 
India copying us.’
Wits ethicist Professor Ames Dhai: 
‘You cannot use un-researched 
interventions in the name of 
therapy. You can’t hide behind 
therapy. It must stand up to 
systematic, scientific scrutiny and 
we don’t have that yet.’
